Diapositive 1



First-line use of Bevacizumab did not improve OS



PFS was prolonged, but did not reach the prespecifiec improvement target (-30% reduction )

Alternative drugs: Bevacizumab (RTOG 0825)

Gilbert MR. et al. NEJM 2014:370

Median PFS

10.7 vs 7.3 months

Median OS

15.7 vs 16.1 months